Dizal Pharmaceutical receives $600 million upfront payment from AstraZeneca; Penghua STAR Market Healthcare ETF's underlying index rises nearly 3%

Jiemian·30 Sep 2026·

·Read original

4▲2 ▼0Impact / 5

M&A · Partnership Industry Pharmaceuticals

688192.CG ▲

AZN.LSE ▲

Summary · why it matters

Dizal Pharmaceutical announced that on July 14, 2026, it signed a license agreement with AstraZeneca, granting AstraZeneca exclusive global rights to develop and commercialize sunvozertinib. The agreement took effect on August 31, 2026, and the company recently received a $600 million upfront payment from AstraZeneca. Boosted by this news, as of 10:09 a.m. on September 30, 2026, the underlying index of the Penghua STAR Market Healthcare ETF, the SSE STAR Market Biomedical Index, rose 2.85%, with constituent stocks CanSino Biologics up 20.00%, Vazyme up 11.89%, and Anhui Huaheng Biotechnology up 8.45%. The underlying index of the Penghua Hong Kong Stock Connect Healthcare ETF, the CSI Hong Kong Stock Connect Healthcare Composite Index, rose 2.16%. In addition, the latest post-hoc analysis of the Phase 3 clinical study in China of telitacicept for generalized myasthenia gravis, published on September 29, showed that more than 94% of patients achieved at least a 5-point improvement in MG-ADL score, and among patients who achieved MSE, 86.7% maintained MSE status at the next monthly assessment. Orient Securities pointed out that improving industry profit margins and the ramp-up of innovative products are jointly driving profit release, with CXO and innovative biologics becoming the strongest boom sectors. If innovative drugs continue to deliver profits in the second half of the year and CXO orders smoothly translate into revenue, the market's pricing logic for the pharmaceutical sector is expected to shift from low-valuation repair to a reassessment of the earnings sustainability of high-quality growth assets.

Dizal (Jiangsu) Pharmaceutical Co. Ltd. A ▲

AstraZeneca PLC ▲